ForSight Robotics vs Eikon Therapeutics
Side-by-side comparison of AI visibility scores, market position, and capabilities
Ophthalmic robotics company raised $125M Series B in Jun 2025; first human cataract trials launching 2026; Oryom robot designed to reach any point within the human eye for cataract, retinal, and glaucoma procedures with precision exceeding human surgical capability.
About
ForSight Robotics is developing the Oryom — a surgical robot designed to reach any anatomical point within the human eye, enabling robotic cataract surgery, retinal procedures, and glaucoma interventions with precision exceeding human capability. The company raised $125 million in Series B financing in June 2025 and is launching its first human cataract trials in 2026, making it one of the most clinically advanced ophthalmic robotics companies globally. If the 2026 trial results are positive, an FDA submission pathway follows for the world's first robotic eye surgery system at clinical scale.
Raised $381M IPO on Nasdaq (Feb 2026, EIKN). Proprietary RESOLFT super-resolution microscopy tracks single protein molecules in living cells. Creates new drug discovery data category.
About
Eikon Therapeutics is a drug discovery company that went public on Nasdaq in February 2026 (ticker: EIKN) with a $381 million IPO, armed with a proprietary RESOLFT super-resolution microscopy platform that tracks individual protein molecules in living cells in real time. Unlike computational drug discovery approaches that model proteins in isolation, Eikon's platform observes how proteins actually behave within the complex, dynamic environment of living cells — generating a new category of drug discovery data that no other method can produce.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.